Leiden, The Netherlands, 14 November 2016: Pharming Group N.V. (the “Company”) (EURONEXT: PHARM) today announced that the results of its “Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human C1 Inhibitor for Prophylaxis of Hereditary Angioedema Attacks”, were presented by Marco Cicardi, Professor of Internal Medicine University of Milan, Hospital L. Sacco Milan and co-prinicipal investigator for the study. The presentation was held during the American College of Allergy, Asthma and Immunology 2016 Scientific Meeting (“ACAAI”) meeting in San Francisco yesterday afternoon.

Available for download here.